BLSH
Bullish
BLSH has lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over BLSH overall, supported by stronger fundamentals and stronger modeled upside.
BLSH Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Stable | |
| Under pressure |
BLSH's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
BLSH PE Valuation
BLSH has no meaningful PE right now: it lost money over the past year.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK's PE is 7.5x, but its earnings don't support one, so it isn't a reliable read right now.
BLSH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BLSH, with profitability improving. However, they disagree widely on these estimates.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for SNDK, with profitability improving.
BLSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | — |
| Q2 2026 | -$9.12 | -$8.12 |
| Q1 2026 | -$6.60 | -$4.07 |
| Q4 2025 | -$5.10 | -1062% |
BLSH lost $9.12 per share over the past year, and its loss has widened in each of the last three quarters.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over BLSH in the latest year-over-year earnings comparison.
BLSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $92.6M | -100% |
| Q1 2026 | $51.8B | -35% |
| Q4 2025 | $64.4B | -2.5% |
| Q3 2025 | $41.6B | -23% |
| Q2 2025 | $58.7B | +18% |
| Q1 2025 | $80.3B | -0.2% |
BLSH's revenue has slid since its 2024 peak: $93M last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 6.6% | +6.6 points |
| Q1 2026 | -0.1% | -0.1 points |
| Q4 2025 | 0% | 0 points |
| Q3 2025 | 0.1% | +0.1 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | 0% | 0 points |
| Q4 2024 | 0% | N/A |
| Q3 2024 | 0% | N/A |
BLSH's operating margin was 6.6% last quarter, up 6.6 points from the same quarter a year ago, near the top of its range since 2024.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK has the edge over BLSH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over BLSH on profitability, with a higher operating margin.
BLSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.1M | -88% |
| Q1 2026 | $89.6M | +$134.9M |
| Q4 2025 | $54.1M | +52% |
| Q3 2025 | -$48.7M | -$38.8M |
| Q2 2025 | $16.8M | +25% |
| Q1 2025 | -$45.3M | +$27.4M |
BLSH's free cash flow has turned positive again: $97M over the past year, against −$3M the year before.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the edge over BLSH on cash flow, with more consistent year-over-year improvement.
BLSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +270K shares |
| 1 year | +3.6% | +5.2M shares |
BLSH has 151M diluted shares, up 3.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BLSH hasn't bought back shares in the past year.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has the edge over BLSH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
BLSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | 3.9x | Elevated |
BLSH's net debt is about 3.9 years of its operating earnings (EBITDA).
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has more cash than debt.
BLSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.1 | Neutral |
| Stochastic | 12.1 | Oversold |
BLSH's weekly RSI is 39 (neutral) and its Stochastic is 12 (oversold).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
BLSH PE vs Technology Sector
BLSH has no meaningful PE right now: it lost money over the past year.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK is trading at 7.5x earnings, a 73% discount to the Technology sector's median of 28x, though its earnings don't support one.
BLSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 20% below |
| 20 week MA | $28.5 | 19% below |
| 50 week MA | $32.8 | 29% below |
BLSH and SNDK share similar trend alignment, each above 0 of 3 tracked weekly averages.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
BLSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $69.5 | $41.1 | -41% |
| 2026 YTD | $41.1 | $23.2 | -44% |
BLSH has finished every year since 2025 lower, and it's down 44% so far in 2026.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over BLSH on returns for 2026, with the stronger performance.